In addition, an in vivo study recently demonstrated improved survival (orthotopic melanoma tumors) and slower tumor growth with SuccFerr-loaded LNC (intraperitoneal injection) compared to anti-CTLA4 mAb [31]. This evidence concerns the gene CTLA4 and melanoma.